About AFG1-like ATPase
AFG1-like ATPase (AFG1L) is a protein
from Homo sapiens identified by UniProt accession
Q8WV93, 481 residues long.
MolForge cross-references it against 0 known binders and
53 disease associations.
Target properties
| Protein name | AFG1-like ATPase |
| UniProt accession | Q8WV93 |
| Gene | AFG1L |
| Organism | Homo sapiens |
| Length | 481 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (53)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.19
- Griscelli syndrome type 3 · score 0.09
- ringed hair disease · score 0.08
- uncombable hair syndrome · score 0.08
- Griscelli disease · score 0.08
- Griscelli disease type 3 · score 0.08
- microcephaly-albinism-digital anomalies syndrome · score 0.06
- Microcephaly - albinism - digital anomalies · score 0.06
- pili bifurcati · score 0.06
- Griscelli disease type 1 · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8WV93-F1 | alphafold | PREDICTED | 78.14 | — |
Amino-acid sequence (481 residues)
MAASWSLLVT LRPLAQSPLR GRCVGCGAWA AALAPLATAP GKPFWKAYTV QTSESMTPTA TSETYLKALA VCHGPLDHYD FLIKAHELKD DEHQRRVIQC LQKLHEDLKG YNIEAEGLFS KLFSRSKPPR GLYVYGDVGT GKTMVMDMFY AYVEMKRKKR VHFHGFMLDV HKRIHRLKQS LPKRKPGFMA KSYDPIAPIA EEISEEACLL CFDEFQVTDI ADAMILKQLF ENLFKNGVVV VATSNRPPED LYKNGLQRAN FVPFIAVLKE YCNTVQLDSG IDYRKRELPA AGKLYYLTSE ADVEAVMDKL FDELAQKQND LTRPRILKVQ GRELRLNKAC GTVADCTFEE LCERPLGASD YLELSKNFDT IFLRNIPQFT LANRTQGRRF ITLIDNFYDL KVRIICSAST PISSLFLHQH HDSELEQSRI LMDDLGLSQD SAEGLSMFTG EEEIFAFQRT ISRLTEMQTE QYWNEGDRTK K
Explore AFG1-like ATPase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets